Zobrazeno 1 - 10
of 560
pro vyhledávání: '"MINMING LI"'
Autor:
Ye Jin, Jun Zhao, Tangkai Qi, Di Tian, Yixin Liao, Qing Yang, Minming Li, Qingqing Zhu, Jun Chen, Yinzhong Shen, Yabin Liu, Hongzhou Lu
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionIn the course of immune development, HIV-exposed uninfected (HEU) infants exhibit abnormal immune function and increased infectious morbidity compared to HIV-unexposed uninfected (HUU) infants. Yet the specific functional phenotypes and r
Externí odkaz:
https://doaj.org/article/891a96d2614e4d4098285fc9eadb9e93
Autor:
Xiaomei Chen, Chao Li, Yulian Wang, Suxia Geng, Maozhi Xiao, Lingji Zeng, Chengxin Deng, Minming Li, Xin Huang, Jianyu Weng, Xin Du, Peilong Lai
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTThis study delves into the emerging role of ferroptosis in Myelodysplastic Neoplasms (MDS) and aims to identify a prognostic ferroptosis-related gene signature for MDS. Utilizing RNA-seq data and clinical information from the Gene Expression
Externí odkaz:
https://doaj.org/article/ce27c683265f4a74a24ebf72ffb89c5f
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 17 (2023)
Ferroptosis is a regulatory cell death characterized by intracellular iron accumulation and lipid peroxidation that leads to oxidative stress. Many signaling pathways such as iron metabolism, lipid metabolism, and amino acid metabolism precisely regu
Externí odkaz:
https://doaj.org/article/c94370f5edba44cd814e41a3a2430456
Autor:
Xin Huang, Cunte Chen, Mengjun Zhong, Suxia Geng, Yujie Zhao, Minming Li, Chenxin Deng, Lingji Zeng, Ping Wu, Zesheng Lu, Jianyu Weng, Xin Du, Yangqiu Li
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-5 (2021)
Abstract Myelodysplastic syndrome (MDS) is an aggressive and genetically heterogeneous disease with poor prognosis. Cellular immune disorder is a common characteristic of this disease and is thought to be related to clinical outcome. Alterations in T
Externí odkaz:
https://doaj.org/article/fe401c4529e047ea846b89e606435bc8
Autor:
Suxia Geng, Ruohao Xu, Xin Huang, Minming Li, Chengxin Deng, Peilong Lai, Yulian Wang, Ping Wu, Xiaomei Chen, Jianyu Weng, Xin Du
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidenc
Externí odkaz:
https://doaj.org/article/c4f90879820d4bb0a080d4069b6b6fc0
Autor:
Jinghua Wang, Zewei Zhuo, Yanjun Wang, Shuo Yang, Jierong Chen, Yulian Wang, Suxia Geng, Minming Li, Xin Du, Peilong Lai, Jianyu Weng
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2022)
Background: Emerging evidence has proven that ferroptosis plays an important role in the development of acute myeloid leukemia (AML), whereas the exact role of ferroptosis-associated genes in AML patients’ prognosis remained unclear.Materials and M
Externí odkaz:
https://doaj.org/article/7945e019d3594e0f8d3f55b428d3e459
Autor:
Ling Xu, Lian Liu, Danlin Yao, Xiangbo Zeng, Yikai Zhang, Jing Lai, Jun Zhong, Xianfeng Zha, Runhui Zheng, Yuhong Lu, Minming Li, Zhenyi Jin, Sudheendra Hebbar Subramanyam, Shaohua Chen, Xin Huang, Yangqiu Li
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple cancers, evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains inadequate. Further exploration of the causes of immune evasion in the bone m
Externí odkaz:
https://doaj.org/article/0530309469c6485484285932f806bf03
Autor:
MinMing Li, Chao Li, SuXia Geng, XiaoMei Chen, Ping Wu, ChengXin Deng, XiaoFang Chen, ZeSheng Lu, JianYu Weng, Xin Du
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The treatment outcomes of intermediate or high-risk myelodysplastic syndrome (MDS) remain unsatisfactory. This study was designed to evaluate the safety and efficacy of human leukocyte antigen (HLA)-mismatched hematopoietic stem cell micro-transplant
Externí odkaz:
https://doaj.org/article/cad7c64864014820a7031da874ba039b
Autor:
NINGYU LI, XIAOFANG CHEN, SUXIA GENG, PEILONG LAI, LISI HUANG, MINMING LI, XIN HUANG, CHENGXIN DENG, YULIAN WANG, JIANYU WENG, XIN DU
Publikováno v:
BIOCELL. 47:133-141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a562bbd879e103ec7d43494ace520b8
https://doi.org/10.32604/biocell.2022.022021
https://doi.org/10.32604/biocell.2022.022021
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Immunotherapies have advanced the treatment of metastatic melanoma; however, they are associated with immune-related toxicities. Patients with pre-existing autoimmune comorbidities are commonly excluded from clinical trials invest
Externí odkaz:
https://doaj.org/article/a7ecd5ff737d4e8cb8179faa213d8f20